Top

Journal of Clinical Immunology

Published in:

01-11-2021 | Primary Immunodeficiency | Letter to Editor

Perceptions Around Lung Transplant–Associated Hypogammaglobulinemia

Authors: Joey Lew, Megan Casey, Lorriana E. Leard, Steven Hays, Iris M. Otani

Published in: Journal of Clinical Immunology | Issue 8/2021

Excerpt

To the Editor: …

Petrov AA, Traister RS, Crespo MM, et al. A prospective observational study of hypogammaglobulinemia in the first year after LT. Transplant Direct. 2018;4(8):e372. https://doi.org/10.1097/TXD.0000000000000811.CrossRefPubMedPubMedCentral

Florescu DF, Kalil AC, Qiu F, Schmidt CM, Sandkovsky U. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant. 2013;13(10):2601–10. https://doi.org/10.1111/ajt.12401.CrossRefPubMed

Bourassa-Blanchette S, Patel V, Knoll GA, Hutton B, Fergusson N, Bennett A, Tay J, Cameron DW, Cowan J. Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: a systematic review and meta-analysis - Part II: Non-kidney transplant. Clin Transplant. 2019;33(7):e13625. https://doi.org/10.1111/ctr.13625.CrossRefPubMed

Kaplan B, Bonagura VR. Secondary hypogammaglobulinemia: an increasingly recognized complication of treatment with immunomodulators and after solid organ transplantation. Immunol Allergy Clin North Am. 2019;39(1):31–47. https://doi.org/10.1016/j.iac.2018.08.005.CrossRefPubMed

Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, El-Gamal Y, Harville TO, Hossny E, Mazer B, Nelson R, Secord E, Jordan SC, Stiehm ER, Vo AA, Ballow M. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1–46. https://doi.org/10.1016/j.jaci.2016.09.023.CrossRefPubMed

Title: Perceptions Around Lung Transplant–Associated Hypogammaglobulinemia
Authors: Joey Lew
Megan Casey
Lorriana E. Leard
Steven Hays
Iris M. Otani
Publication date: 01-11-2021
Publisher: Springer US
Keyword: Primary Immunodeficiency
Published in: Journal of Clinical Immunology / Issue 8/2021
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-021-01111-6

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Perceptions Around Lung Transplant–Associated Hypogammaglobulinemia

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2021

Simple Measurement of IgA Predicts Immunity and Mortality in Ataxia-Telangiectasia

Second Tier Testing to Reduce the Number of Non-actionable Secondary Findings and False-Positive Referrals in Newborn Screening for Severe Combined Immunodeficiency

NBAS Variants Are Associated with Quantitative and Qualitative NK and B Cell Deficiency

Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona

Undetectable NK Cells due to the FCGR3A Variant, L66H, Which May Not Be Directly Disease-Causing

Prolonged Fecal Shedding of SARS-CoV-2 in Asymptomatic Children with Inborn Errors of Immunity

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page